
|Videos|April 20, 2022
Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Half a Year Into the Breast Biopsy Needle Shortage, Clinicians Lean on Networks, Not Workarounds
2
How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?
3
Study Redefines Functional High-Risk Multiple Myeloma in Modern-Therapy Era
4
First-in-Human mKRAS Vaccine Elicits Durable T-Cell Responses in High-Risk PDAC
5

































































